Here are three things to know.
1. Bristol-Myers will license an experimental drug to Biogen for progressive supranuclear palsy, a rare neurodegenerative brain disorder. The drug may also prove viable for treating Alzheimer’s disease, according to Biogen, which will pay $300 million for the drug.
2. Roche will pay $170 million to receive the licensing rights for Bristol-Myers’ investigational Duchenne muscular dystrophy drug.
3. Bristol-Myers expects the deals to close in the second quarter.
More articles on supply chain:
FDA rejects Eli Lilly’s arthritis drug
Lannett CEO gloats about generic price hikes, investors say
Drug shortages raise price of alternative treatments: 4 study findings
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
